Dr. Martin Pelletier is a researcher in the Division of Infectious and Immune Diseases at the CHU de Québec-Laval University Research Center, and Assistant Professor in the Department of Microbiology-Infectious Diseases and Immunology at Laval University. Author of over 35 publications, he has developed a unique expertise in inflammation, innate immunity, and energy metabolism. His research program focuses on the identification of intrinsic and extrinsic factors involved in triggering, maintaining, and resolving inflammation. Funded by the CIHR, NSERC, Fondation du Grand défi Pierre Lavoie, Crohn & Colitis Canada and Rare Disease Foundation, his work aims at characterizing environmental and host factors that modulate energy metabolism and the functional responses of inflammatory cells in chronic diseases to develop new therapeutic strategies and improve patient care.

Portray the bioenergetic events involved in inflammatory cells’ aberrant activation in chronic diseases such as inflammatory arthritis and inflammatory bowel disease

Pro-inflammatory mediators such as cytokines, actively participate in the progression and severity of inflammatory diseases. These mediators modulate the functional responses of inflammatory cells such as neutrophils and monocytes. Very little is known, however, about the metabolic changes that occur systemically in the patients. The characterization of the molecular mechanisms underlying altered energy metabolism in inflammatory chronic diseases such as gout, rheumatoid arthritis and colitis could provide the foundation for new personalized therapeutic treatments of chronic inflammatory diseases that specifically modulate bioenergetics of pathogenic immune cells.

Characterize the effects of widely used endocrine-disrupting chemicals on the bioenergetics of inflammatory cells

Endocrine-disrupting chemicals are natural or synthetic compounds that can alter endocrine functions, often through mimicking or blocking endogenous hormones, and are linked to cancer, obesity and autoimmune diseases. These chemicals include pesticides, herbicides, plasticizers (bisphenol A and phthalates), pharmaceuticals, and cosmetics. The widespread use of endocrine-disrupting chemicals leads to their distribution in the environment, as well as human exposure, as evidenced by their presence in human tissues and biological fluids, such as blood and urine. Understanding the effects of endocrine-disrupting chemicals on the bioenergetics of the most abundant inflammatory cells in the blood, namely neutrophils and monocytes, could explain their immunomodulatory activities, and how these chemicals can contribute to inflammation or increased susceptibility to infections.

Development of a clinical assay to classify and guide the personalized treatment of rare auto-inflammatory patients

Recurrent fevers, systemic/organ-specific inflammation and hyperreactive innate immune cells linked to abnormal cytokine secretion are characteristics of auto-inflammatory syndromes. While being inherited conditions, mutations in patients with high suspicion for auto-inflammatory syndromes are detected in less than 20% of cases, and patients bear confounding phenotypes with systemic autoimmune rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus. Although anti-cytokine therapeutics are available, auto-inflammatory syndrome treatments are often inefficient because information on the specific cytokines abnormally secreted in each patient is overlooked, leading not only to inappropriate treatment, but also to severe complications, with important repercussions on the patient’s health, his family, and bring about substantial socio-economic costs. The quantification of the cytokines abnormally secreted should not only help the diagnosis, but also provide personalized treatment options to auto-inflammatory syndrome patients.

CHUL
2705, boulevard Laurier
T-1-49
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

55 entries « 1 of 6 »

Lacouture A, Lafront C, Peillex C, Pelletier M, Audet-Walsh É

Impacts of endocrine-disrupting chemicals on prostate function and cancer.

Journal Article

Environ Res, 204 (Pt B), 2021.

Abstract | Links:

Gamara J, Davis L, Leong AZ, Pagé N, Rollet-Labelle E, Zhao C, Hongu T, Funakoshi Y, Kanaho Y, Aoudji F, Pelletier M, Bourgoin SG

Arf6 regulates energy metabolism in neutrophils.

Journal Article

Free Radic Biol Med, 172 , 2021.

Abstract | Links:

Lacouture A, Jobin C, Weidmann C, Berthiaume L, Bastien D, Laverdière I, Pelletier M, Audet-Walsh É

A FACS-Free Purification Method to Study Estrogen Signaling, Organoid Formation, and Metabolic Reprogramming in Mammary Epithelial Cells.

Journal Article

Front Endocrinol (Lausanne), 12 , 2021.

Abstract | Links:

Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Pelletier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, Dubois A, Joshi AY, Waters DD, Hsue P, Lepor NE, Lesage F, Sainturet N, Roy-Clavel E, Bassevitch Z, Orfanos A, Stamatescu G, Grégoire JC, Busque L, Lavallée C, Hétu PO, Paquette JS, Deftereos SG, Levesque S, Cossette M, Nozza A, Chabot-Blanchet M, Dubé MP, Guertin MC, Boivin G

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.

Journal Article

Lancet Respir Med, 9 (8), 2021.

Abstract | Links:

Vaillancourt M, Desaulniers P, Paré G, Pagé N, Lachhab A, Kerever A, Julien AS, Amiable N, Pelletier M, Tessier PA, Bessette L, Michou L, Fortin PR, Fernandes MJ

Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis.

Journal Article

Sci Rep, 11 (1), 2021.

Abstract | Links:

Saba I, Barat C, Chabaud S, Reyjon N, Leclerc M, Jakubowska W, Orabi H, Lachhab A, Pelletier M, Tremblay MJ, Bolduc S

Immunocompetent Human 3D Organ-Specific Hormone-Responding Vaginal Mucosa Model of HIV-1 Infection.

Journal Article

Tissue Eng Part C Methods, 27 (3), 2021.

Abstract | Links:

Poluri RT, Paquette V, Allain EP, Lafront C, Joly-Beauparlant C, Weidmann C, Droit A, Guillemette C, Pelletier M, Audet-Walsh E

KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism.

Journal Article

Endocr Relat Cancer, 28 (4), 2021.

Abstract | Links:

Pellerin E, Caneparo C, Chabaud S, Bolduc S, Pelletier M

Endocrine-disrupting effects of bisphenols on urological cancers.

Journal Article

Environ Res, 195 , 2021.

Abstract | Links:

Peillex C, Kerever A, Lachhab A, Pelletier M

Bisphenol A, bisphenol S and their glucuronidated metabolites modulate glycolysis and functional responses of human neutrophils.

Journal Article

Environ Res, 196 , 2021.

Abstract | Links:

Peillex C, Pelletier M

The impact and toxicity of glyphosate and glyphosate-based herbicides on health and immunity.

Journal Article

J Immunotoxicol, 17 (1), 2020.

Abstract | Links:

55 entries « 1 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche en arthrite (ARThrite), from 2020-11-03 to 2026-04-30
  • Defining the Effects of Endocrine-Disrupting chemicals on the cellular metabolism of inflammatory cells., from 2015-04-01 to 2022-03-31
  • Développement d’une méthode fiable pour la détection d’anticorps contre Malassezia, from 2020-04-01 to 2022-03-31
  • Étude de la réponse immune contre Malassezia dans la maladie de Crohn, from 2018-11-01 to 2021-10-31
  • Métabolisme bioénergétique et réponse fonctionnelle des cellules inflammatoires : Étude de facteurs endogènes et environnementaux, from 2018-07-01 to 2022-06-30
  • Réponse immunitaire contre le champignon Malassezia dans la prostate, from 2019-11-01 to 2021-10-31

Recently finished projects

  • Centre de recherche en arthrite de l'Université Laval, from 2019-01-01 to 2020-01-31
  • CUASF-BCC Research Grant Program , from 2020-06-06 to 2021-06-05
  • Évaluation du profil de cytokines par les leucocytes sanguins : étude d'un cas clinique, from 2020-04-07 to 2021-03-31
  • Projet de recherche sur les maladies auto-inflammatoires, from 2019-04-01 to 2020-03-31
  • Repositionnement du fumarate de diméthyle pour traiter la COVID-19: une molécule à double action au potentiel antiviral et anti-inflammatoire, from 2020-05-11 to 2021-04-30
Data provided by the Université Laval research projects registery